ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 102 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,074,545 | -20.9% | 342,900 | +1.5% | 0.00% | -100.0% |
| Q2 2023 | $2,622,345 | +524.0% | 337,931 | +358.4% | 0.00% | – |
| Q1 2023 | $420,221 | -2.2% | 73,723 | +1.1% | 0.00% | – |
| Q4 2022 | $429,570 | +83.6% | 72,932 | -0.4% | 0.00% | – |
| Q3 2022 | $234,000 | -28.0% | 73,239 | +1.0% | 0.00% | – |
| Q2 2022 | $325,000 | -79.6% | 72,525 | -75.7% | 0.00% | – |
| Q1 2022 | $1,596,000 | -65.4% | 298,858 | -4.8% | 0.00% | -100.0% |
| Q4 2021 | $4,613,000 | -30.4% | 313,783 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $6,624,000 | +34.7% | 316,808 | +14.0% | 0.00% | 0.0% |
| Q2 2021 | $4,916,000 | -13.1% | 277,891 | +20.4% | 0.00% | 0.0% |
| Q1 2021 | $5,654,000 | -29.5% | 230,757 | -2.7% | 0.00% | -50.0% |
| Q4 2020 | $8,024,000 | +202.9% | 237,047 | +123.8% | 0.00% | +100.0% |
| Q3 2020 | $2,649,000 | -29.2% | 105,922 | -4.4% | 0.00% | 0.0% |
| Q2 2020 | $3,739,000 | – | 110,852 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |